Solitary liver metastasis is a distinct subdivision of colorectal cancer associated favorable progno

来源 :第十二届全国大肠癌学术会议暨江苏省第九届腹腔镜外科会议 | 被引量 : 0次 | 上传用户:yu19910108
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  BACKGROUND/AIMS: Colorectal cancer with liver metastasis is the most commonly advanced stage.We proposed that patients with solitary liver metastasis should be classified as a distinct subdivision with better survival than patients with multiple liver metastases.METHODS: We collected 445 patients diagnosed with only liver metastasis from colorectal cancer, and divided them into two groups: solitary liver metastasis group and multiple liver metastases group.The corresponding colorectal cancer-specific survival data were also obtained.We used Kaplan-Meier method, Cox regression analysis to estimate the relationship between the number of liver metastasis and prognosis of patients.RESULTS: The median cancer-specific survival was 21.0 months in solitary liver metastasis group, as compared with 14.0 months in multiple liver metastases group.Patients in solitary liver metastasis group had better 5-year cancer-specific survival than those in multiple liver metastases group based on Kaplan-Meier method.Results in both univariate and multivariate analysis also suggested that number of liver metastasis was an independent prognostic factor for survival outcome.In addition, this finding was also confirmed by further analysis in 24 subgroups which were confined by demographic and clinicopathologic characteristics.CONCLUSIONS: Colorectal cancer with solitary liver metastasis was found to be a distinct subdivision with a favorable prognosis.
其他文献
Background The flotillin family member flotillin-1 (FLOT1) encodes a caveolae-associated, integral membrane protein that belongs to lipid raft family and involv
会议
  目的:急性毒性是直肠癌患者同步放化疗的主要剂量限制性因素,其发生过程与一些致炎性细胞因子相关,包括白介素-1 (interleukin-1,IL-1),白介素-6和肿瘤坏死性因子-α (tum
会议
通过对131例肠造口术后患者家属的跟踪调查,发现造口患者家属术后早期的造口护理参与情况并不高,尤其是撕离造口袋、清洁皮肤等需要碰触造口的护理步骤。家属年龄越大对于造口
  目的:探讨胃肠道肿瘤患者术后发生肺栓塞的特点,总结临床诊治经验及防治策略.方法:回顾性分析2010年1月至2013年6月我院19例胃肠道肿瘤术后发生肺栓塞患者的临床资料.结果:1
  目的:纤溶酶原激活物抑制剂-1 (PAI-1)和蛋白酶激活受体-1(PAR-1)是肠道微环境的重要介质,参与肠道的放射性急性和慢性损伤.为了评价PAI-1和PAR-1的基因多态性是否能够预测
会议
肝切除是肝转移癌患者唯一可以获得长期生存的选择。MDT模式是获得最佳治疗策略的根本,结合现实国情,强调个体化治疗,只有最有利的方案,没有最正确的方案。
  INTRODUCTION: Natural orifice specimen extraction (NOSE) surgery prevents the need for mini-laparotomy to extract the surgical specimen, which avoid wound i
会议
大约25%的结直肠癌患者存确诊时就合并同时性的肝转移,并且大多数转移灶不可切除.对于结直肠癌伴有不可切除肝转移的患者最佳的治疗方案是化疗后行原发肿瘤切除术(PTR),还是直
腹腔镜在结直肠癌肝转移同步切除中微创优势明显,肠镜不能通过时留个心眼:多原发癌,腹腔镜结肠切除,术前纳米碳定位,肝转移灶切除,术中B超定位,注意切口选择(一口多用)。
  目的:探讨直肠癌前切除手术术后吻合口瘘的相关危险因素.方法:回归分析2008年12月-2013年12就诊北京大学肿瘤医院707例行直肠前切除手术的直肠癌患者临床病例资料,分析影响
会议